How Does the Patient Benefit from Clinical PET?
Open Access
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 2 (5), 427-436
- https://doi.org/10.7150/thno.3794
Abstract
Clinical molecular imaging by use of PET and PET/CT is increasingly important in routine oncological practice worldwide. A vast majority of clinical PET investigations are performed with [18F]-fluorodeoxyglucose (FDG), but there is a growing interest in novel molecular probes among scientists and clinicians. Beyond FDG, a small number of different tracers have been shown to be of clinical value. With a growing commercial interest in tracer development, many more are under investigation. This review provides some examples of clinical situations where tracers other than FDG have been found useful and an outlook towards technical and regulatory development needed to allow the full impact of clinical PET to benefit the individual patient.Keywords
This publication has 32 references indexed in Scilit:
- Positron Emitting [68Ga]Ga-Based Imaging Agents: Chemistry and DiversityMedicinal Chemistry, 2011
- Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the FutureMolecular Imaging & Biology, 2011
- Clinical amyloid imaging in Alzheimer's diseaseThe Lancet Neurology, 2011
- Accuracy of whole‐body PET and PET‐CT in initial M staging of head and neck cancer: A meta‐analysisHead & Neck, 2011
- PET Imaging of Integrin αVβ3 ExpressionTheranostics, 2011
- Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studiesNuclear Medicine Communications, 2009
- Positron Emission Tomography/Computed Tomography for Target Delineation in Head and Neck CancersSeminars in Nuclear Medicine, 2008
- Genotoxic hazard of radiopharmaceuticals in humans: chemical and radiation aspects coupled to microdosingEuropean Journal of Clinical Pharmacology, 2007
- Pheochromocytomas: Detection with11C Hydroxyephedrine PETRadiology, 2004
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyThe New England Journal of Medicine, 2003